SRP-001

SRP-001 (32-100 mg/kg; p.o.; administered cumulatively at 60 min intervals) produces dose-dependent analgesic effects in juvenile male Sprague-Dawley rats with CFA-induced inflammatory pain, and increases their paw withdrawal thresholds to mechanical and thermal stimuli^[1].
SRP-001 (32-100 mg/kg; p.o.) exerts analgesic effects in aged male Sprague-Dawley rats with inflammatory pain induced by complete Freund's adjuvant (CFA), and its efficacy is comparable to that of acetaminophen (ApAP) at equivalent doses^[1].
SRP-001 (32-100 mg/kg; p.o.; single administration) produces dose-dependent analgesic effects in visceral pain models of juvenile mice, aged male mice, and juvenile female mice^[1].
SRP-001 (75 mg/kg; p.o.; single administration) exerts antipyretic activity in yeast-induced febrile male CD1 mice, and its core body temperature-lowering effect is similar to that of 75 mg/kg ApAP^[1].
SRP-001 (32 mg/kg; i.p.; single administration) produces higher levels of the analgesic metabolite AM404 in the periaqueductal gray (PAG) of Sprague-Dawley rats than 32 mg/kg of ApAP, which provides support for its antinociceptive mechanism of action^[1].